These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies. Halpenny D; O'Dwyer E; Girshman J; Ginsberg MS J Thorac Imaging; 2020 Jan; 35(1):26-36. PubMed ID: 31855947 [TBL] [Abstract][Full Text] [Related]
6. Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis. Birch JC; Khatri G; Watumull LM; Arriaga YE; Leyendecker JR Radiographics; 2018; 38(4):1158-1179. PubMed ID: 29995613 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in oncology: a new challenge for radiologists. Bustos Fiore A; Gutiérrez AB; Acosta LG; Segura Cros C; Ramos de la Rosa R Radiologia (Engl Ed); 2019; 61(2):134-142. PubMed ID: 30580817 [TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
9. PET/CT: will it change the way that we use CT in cancer imaging? Hicks RJ; Ware RE; Lau EW Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079 [TBL] [Abstract][Full Text] [Related]
10. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma. Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707 [TBL] [Abstract][Full Text] [Related]
11. Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events. Elsherif SB; Anderson M; Chaudhry AA; Kumar SP; Gopireddy DR; Lall C; Bhosale PR Eur J Radiol; 2022 Jan; 146():110062. PubMed ID: 34890935 [TBL] [Abstract][Full Text] [Related]
12. Treatment after progression in the era of immunotherapy. Billan S; Kaidar-Person O; Gil Z Lancet Oncol; 2020 Oct; 21(10):e463-e476. PubMed ID: 33002442 [TBL] [Abstract][Full Text] [Related]
13. Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. Lennartz S; Diederich S; Doehn C; Gebauer B; Grünwald V; Notohamiprodjo M; Sommer W; Schlemmer HP; Persigehl T Rofo; 2020 Mar; 192(3):235-245. PubMed ID: 31994155 [TBL] [Abstract][Full Text] [Related]
14. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Torrisi JM; Schwartz LH; Gollub MJ; Ginsberg MS; Bosl GJ; Hricak H Radiology; 2011 Jan; 258(1):41-56. PubMed ID: 21183492 [TBL] [Abstract][Full Text] [Related]
15. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232 [TBL] [Abstract][Full Text] [Related]
16. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? Madden DL Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148 [TBL] [Abstract][Full Text] [Related]
17. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Souza FF; Smith A; Araujo C; Jagannathan J; Johnston C; O'Regan K; Shinagare A; Ramaiya N Cancer Imaging; 2014 Jul; 14(1):26. PubMed ID: 25608887 [TBL] [Abstract][Full Text] [Related]
18. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. Bossi P; Botta L; Bironzo P; Sonetto C; Musettini G; Sbrana A; Di Giannantonio V; Locati LD; Di Maio M; Antonuzzo A Future Oncol; 2019 Jul; 15(21):2543-2553. PubMed ID: 31240949 [No Abstract] [Full Text] [Related]
19. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment]. Szekanecz É; Szekanecz Z Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880 [TBL] [Abstract][Full Text] [Related]
20. Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Guler E; Smith DA; Somarouthu B; Gujrathi R; Ramaiya NH; Tirumani SH Abdom Radiol (NY); 2020 Mar; 45(3):828-841. PubMed ID: 31396642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]